Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 24% of the time (231 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: of ageyears ofchildrencelltransplant
  Phrases that lowered it: patients wholeukemiabreastmgpatients with
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 5.6% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 209 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 23.5% (raises risk) · Drug's FDA history
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past trials: 303 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 94.2% (raises risk) · Drug's FDA history
• Maximum age: 21 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) NCT03526250 · started 2018 · scored riskier than 62% of active trials completed
• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma NCT01403415 · started 2011 · scored riskier than 38% of active trials completed
• Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT03323034 · started 2018 · scored riskier than 23% of active trials completed
• Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia NCT03515200 · started 2018 · scored riskier than 52% of active trials terminated
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 · started 2011 · scored riskier than 22% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.